Brief: Entera Bio Submits Streamlined Phase 3 Protocol To Initiate Registrational Program For Eb613 In Postmenopausal Women With Osteoporosis
04/03/2026 13:31
March 4 (Reuters) - Entera Bio Ltd 5DT.F: ENTERA BIO SUBMITS STREAMLINED PHASE 3 PROTOCOL TO INITIATE REGISTRATIONAL PROGRAM FOR EB613 IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS ENTERA BIO LTD: TOPLINE DATA ANTICIPATED IN SECOND HALF OF 2028, APPROXIMATELY ONE YEAR EARLIER THAN PREVIOUSLY EXPECTED ENTERA BIO LTD: COMMITS TO A 12-MONTH EXTENSION STUDY TO RUN IN PARALLEL WITH POTENTIAL NDA REVIEW ENTERA BIO LTD: ANTICIPATES FDA FEEDBACK WITHIN 60 DAYS Source text: ID:nGNXbwpB6r Further company coverage: 5DT.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entera Bio
See all newsBrief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement